BIOGNOSYS
14.9.2021 08:02:06 CEST | Business Wire | Press release
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec , a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics , in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease30.7.2026 13:01:00 CEST | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for Early Clinical Development, providing practical guidance on the scientific, clinical, and operational factors shaping the development of emerging B-cell depletion therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730139661/en/ B-cell depletion has become an important area of research in autoimmune disease as developers investigate whether deeper and more sustained depletion may support longer periods of remission and potentially influence immune system recovery. Emerging approaches, including in vivo CAR-T therapies and T-cell engagers, are expanding the range of development strategies available beyond established B-cell-targeting treatments. The white paper looks at the early development decisions sponsors face as t
Industrial Info Resources Launches IIR Envoy™ MCP, Bringing Human-Verified Industrial Intelligence Directly Into AI Through Model Context Protocol30.7.2026 13:00:00 CEST | Press release
Model Context Protocol (MCP) connectivity brings 40 years of human-verified energy and industrial intelligence directly into the AI tools professionals already use. Industrial Info Resources (IIR), a leading provider of energy and industrial market intelligence built on primary research and human verification, today announced the launch of IIR Envoy MCP; this new Model Context Protocol connection plugs IIR's authoritative industrial database directly into the AI platforms professionals already use. As an example, with IIR Envoy MCP, an analyst can ask, "What refinery capacity is offline in Europe since this morning's weather event?" or "Which power plants near Houston have upcoming outages?" and receive an instant, source-cited answer drawn from IIR's live data. As AI becomes increasingly embedded in decision-making tools, the quality of AI-generated insights depends entirely on the quality of the underlying data. IIR Envoy MCP was built on that principle. "The information age was abou
120 Million AI Pay Transactions in a Single Week: AI Shopping Agents Move From Theory to Checkout30.7.2026 12:45:00 CEST | Press release
Agentic commerce is beginning to move from forecast to real-world use in some markets. In China, AI agents are already completing purchases at meaningful scale, and analysts now put the global opportunity at $3–5 trillion by 2030. The debate is shifting as early examples show AI shopping agents completing transactions in some markets. According to NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, its global report The Commerce Revolution: Where East Meets West points to agentic commerce moving from experiment toward everyday infrastructure. According to Ant Group, Alipay AI Pay processed more than 120 million transactions during the week of February 5–11, 2026, while Adobe Analytics reported that traffic from generative AI sources to US retail websites increased by 1,200% between July 2024 and February 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730837106/en/ Agentic commerce is beginning to move fr
Quectel Launches FCE870X and FME170X Tri-band Wi-Fi 7 Modules With Bluetooth 6.0 for Set-top Boxes, Gaming Devices and More30.7.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the FCE870X and FME170X tri-band Wi-Fi 7 modules, powered by the Synaptics SYN4384 chipset and designed for set-top boxes, gaming devices, digital signage, VR/AR headsets, smart gateways and other high-performance connected products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730986067/en/ Quectel launches FCE870X and FME170X tri-band Wi-Fi 7 modules with Bluetooth 6.0 for set-top boxes, gaming devices and more The FCE870X and FME170X share the same high-end feature set and differ only in form factor. The FCE870X Wi-Fi 7 module uses a Compact LCC package for embedded designs, while the FME170X Wi-Fi 7 module uses a Compact M.2 package for modular, slot-based systems. Device makers can choose the option that best fits their platform without compromising wireless performance. “These high-end Wi-Fi 7 modules are engineered to run acro
Singapore Selects Thales for Next-generation AI-powered Air Traffic Management System Serving One of Asia’s Busiest Airspaces30.7.2026 10:00:00 CEST | Press release
To address the rapid growth in air traffic, the Civil Aviation Authority of Singapore (CAAS) has selected Thales to develop Singapore’s NexGen Air Traffic Management System (ATMS) and air traffic control radars. Scheduled to enter operational service by 2030, the NexGen ATMS will enable air traffic controllers to provide air traffic control services safely and efficiently, handling up to one million aircraft movements annually. Powered by advanced cybersecurity and Artificial Intelligence technologies, the NexGen ATMS provides an integrated, highly automated environment that enhances controller decision-making, increases operational efficiency, and further strengthens flight safety. The Civil Aviation Authority of Singapore (CAAS) has awarded Thales a landmark contract to develop a new NexGen Air Traffic Management System (ATMS) and air traffic control radars, marking a major step towards a more efficient, safer and more sustainable aviation ecosystem. The NexGen ATMS will replace the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom